Skip to main content
Premium Trial:

Request an Annual Quote

Lion Bioscience Licenses SRS to AstraZeneca

NEW YORK, February 12 -- Lion Bioscience has licensed its SRS biotechnology platform to AstraZeneca, the company said today.


By taking a global perpetual license, the pharmaceutical company will have access to Lion's SRS integration software as well as the SRS Relational module.


Financial terms of the deal were not disclosed.


Since December, Lion has rolled out a series of SRS licensing announcements, including deals with Italy's Siena Biotech, Eli Lilly and Company, Johnson & Johnson Pharmaceutical Research and Development, and Cellzome.


The Heidelberg, Germany-based bioinformatics company restructured last year, cutting nearly 200 jobs and closing its drug discovery operations.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.